

## HB0230S02 compared with HB0230

~~text~~ shows text that was in HB0230 but was deleted in HB0230S02.

text shows text that was not in HB0230 but was inserted into HB0230S02.

**DISCLAIMER:** This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.

Representative Jennifer Dailey-Provost proposes the following substitute bill:

### CENTER FOR MEDICAL CANNABIS RESEARCH

2023 GENERAL SESSION

STATE OF UTAH

**Chief Sponsor: Jennifer ~~Dailey-Provost~~ Dailey-Provost**

Senate Sponsor: ~~\_\_\_\_\_~~ Evan J. Vickers

---

#### LONG TITLE

##### General Description:

This bill creates the Center for Medical Cannabis Research.

##### Highlighted Provisions:

This bill:

- ▶ defines terms;
- ▶ ~~abolishes~~ modifies membership requirements for members of the Cannabis Research Review Board;
- ▶ creates the Center for Medical Cannabis Research (center) within the University of Utah;
- ▶ requires the Department of Health and Human Services to work with the center to create guidance on medical cannabis use;
- ▶ allows the center to be funded by the Qualified Patient Enterprise Fund; and

## HB0230S02 compared with HB0230

- ▶ establishes the center's duties.

### Money Appropriated in this Bill:

~~{None}~~ This bill appropriates in fiscal year 2024:

- ▶ to the University of Utah - Education and General - Center for Medical Cannabis Research, as an ongoing appropriation:
  - from the Qualified Patient Enterprise Fund, \$650,000.

### Other Special Clauses:

None

### Utah Code Sections Affected:

#### AMENDS:

~~{4-41a-102}~~ 26-61-201, as last amended by Laws of Utah 2022, ~~{Chapters 290,}~~ Chapter 452

~~{26-61a-102, as last amended by Laws of Utah 2022, Chapters 290, 452~~

~~———— 26-61a-105}~~ 26-61a-109, as last amended by Laws of Utah ~~{2022, Chapter 452~~

~~———— 26-61a-201, as last amended by Laws of Utah 2022, Chapters 198, 290 and 452~~  
~~{2019, First Special Session, Chapter 5~~

26-61a-703, as last amended by Laws of Utah 2022, Chapter 97

#### ENACTS:

26-61a-117, Utah Code Annotated 1953

53B-17-1401, Utah Code Annotated 1953

53B-17-1402, Utah Code Annotated 1953

#### ~~{REPEALS:~~

~~———— 26-61-101, as enacted by Laws of Utah 2017, Chapter 398~~

~~———— 26-61-102, as last amended by Laws of Utah 2022, Chapter 452~~

~~———— 26-61-103, as enacted by Laws of Utah 2017, Chapter 398~~

~~———— 26-61-201, as last amended by Laws of Utah 2022, Chapter 452~~

~~———— 26-61-202, as last amended by Laws of Utah 2022, Chapter 415~~

---

*Be it enacted by the Legislature of the state of Utah:*

Section 1. Section ~~{4-41a-102}~~ 26-61-201 is amended to read:

~~{~~ ~~4-41a-102. Definitions:~~

## HB0230S02 compared with HB0230

~~As used in this chapter:~~

~~(1) "Adulterant" means any poisonous or deleterious substance in a quantity that may be injurious to health, including:~~

~~(a) pesticides;~~

~~(b) heavy metals;~~

~~(c) solvents;~~

~~(d) microbial life;~~

~~(e) toxins; or~~

~~(f) foreign matter.~~

~~[(2) "Cannabis Research Review Board" means the Cannabis Research Review Board created in Section 26-61-201.]~~

~~[(3)] (2) "Cannabis" means the same as that term is defined in Section 26-61a-102.~~

~~[(4)] (3) "Cannabis concentrate" means:~~

~~(a) the product of any chemical or physical process applied to naturally occurring biomass that concentrates or isolates the cannabinoids contained in the biomass; and~~

~~(b) any amount of a natural, derivative, or synthetic cannabinoid in the synthetic cannabinoid's purified state.~~

~~[(5)] (4) "Cannabis cultivation byproduct" means any portion of a cannabis plant that is not intended to be sold as a cannabis plant product.~~

~~[(6)] (5) "Cannabis cultivation facility" means a person that:~~

~~(a) possesses cannabis;~~

~~(b) grows or intends to grow cannabis; and~~

~~(c) sells or intends to sell cannabis to a cannabis cultivation facility, a cannabis processing facility, or a medical cannabis research licensee.~~

~~[(7)] (6) "Cannabis cultivation facility agent" means an individual who:~~

~~(a) is an employee of a cannabis cultivation facility; and~~

~~(b) holds a valid cannabis production establishment agent registration card.~~

~~[(8)] (7) "Cannabis derivative product" means a product made using cannabis concentrate.~~

~~[(9)] (8) "Cannabis plant product" means any portion of a cannabis plant intended to be sold in a form that is recognizable as a portion of a cannabis plant.~~

## HB0230S02 compared with HB0230

~~[(10)] (9) "Cannabis processing facility" means a person that:~~

~~(a) acquires or intends to acquire cannabis from a cannabis production establishment;~~

~~(b) possesses cannabis with the intent to manufacture a cannabis product;~~

~~(c) manufactures or intends to manufacture a cannabis product from unprocessed cannabis or a cannabis extract; and~~

~~(d) sells or intends to sell a cannabis product to a medical cannabis pharmacy or a medical cannabis research licensee.~~

~~[(11)] (10) "Cannabis processing facility agent" means an individual who:~~

~~(a) is an employee of a cannabis processing facility; and~~

~~(b) holds a valid cannabis production establishment agent registration card.~~

~~[(12)] (11) "Cannabis product" means the same as that term is defined in Section 26-61a-102.~~

~~[(13)] (12) "Cannabis production establishment" means a cannabis cultivation facility, a cannabis processing facility, or an independent cannabis testing laboratory.~~

~~[(14)] (13) "Cannabis production establishment agent" means a cannabis cultivation facility agent, a cannabis processing facility agent, or an independent cannabis testing laboratory agent.~~

~~[(15)] (14) "Cannabis production establishment agent registration card" means a registration card that the department issues that:~~

~~(a) authorizes an individual to act as a cannabis production establishment agent; and~~

~~(b) designates the type of cannabis production establishment for which an individual is authorized to act as an agent.~~

~~[(16)] (15) "Community location" means a public or private elementary or secondary school, a church, a public library, a public playground, or a public park.~~

~~[(17)] (16) "Cultivation space" means, quantified in square feet, the horizontal area in which a cannabis cultivation facility cultivates cannabis, including each level of horizontal area if the cannabis cultivation facility hangs, suspends, stacks, or otherwise positions plants above other plants in multiple levels.~~

~~[(18)] (17) "Department" means the Department of Agriculture and Food.~~

~~[(19)] (18) "Derivative cannabinoid" means any cannabinoid that has been intentionally created using a process to convert a naturally occurring cannabinoid into another cannabinoid.~~

## HB0230S02 compared with HB0230

~~[(20)] (19) "Family member" means a parent, step-parent, spouse, child, sibling, step-sibling, uncle, aunt, nephew, niece, first cousin, mother-in-law, father-in-law, brother-in-law, sister-in-law, son-in-law, daughter-in-law, grandparent, or grandchild.~~

~~[(21)] (20) (a) "Independent cannabis testing laboratory" means a person that:~~

~~(i) conducts a chemical or other analysis of cannabis or a cannabis product; or~~

~~(ii) acquires, possesses, and transports cannabis or a cannabis product with the intent to conduct a chemical or other analysis of the cannabis or cannabis product.~~

~~(b) "Independent cannabis testing laboratory" includes a laboratory that the department or a research university operates in accordance with Subsection 4-41a-201(14).~~

~~[(22)] (21) "Independent cannabis testing laboratory agent" means an individual who:~~

~~(a) is an employee of an independent cannabis testing laboratory; and~~

~~(b) holds a valid cannabis production establishment agent registration card.~~

~~[(23)] (22) "Industrial hemp waste" means:~~

~~(a) a cannabinoid concentrate; or~~

~~(b) industrial hemp biomass.~~

~~[(24)] (23) "Inventory control system" means a system described in Section 4-41a-103.~~

~~[(25)] (24) "Licensing board" or "board" means the Cannabis Production Establishment Licensing Advisory Board created in Section 4-41a-201.1.~~

~~[(26)] (25) "Medical cannabis" means the same as that term is defined in Section 26-61a-102.~~

~~[(27)] (26) "Medical cannabis card" means the same as that term is defined in Section 26-61a-102.~~

~~[(28)] (27) "Medical cannabis pharmacy" means the same as that term is defined in Section 26-61a-102.~~

~~[(29)] (28) "Medical cannabis pharmacy agent" means the same as that term is defined in Section 26-61a-102.~~

~~[(30)] (29) "Medical cannabis research license" means a license that the department issues to a research university for the purpose of obtaining and possessing medical cannabis for academic research.~~

~~[(31)] (30) "Medical cannabis research licensee" means a research university that the department licenses to obtain and possess medical cannabis for academic research, in~~

## HB0230S02 compared with HB0230

~~accordance with Section 4-41a-901.~~

~~— [(32)] (31) "Medical cannabis treatment" means the same as that term is defined in Section 26-61a-102.~~

~~— [(33)] (32) "Medicinal dosage form" means the same as that term is defined in Section 26-61a-102.~~

~~— [(34)] (33) "Qualified medical provider" means the same as that term is defined in Section 26-61a-102.~~

~~— [(35)] (34) "Qualified Production Enterprise Fund" means the fund created in Section 4-41a-104.~~

~~— [(36)] (35) "Recommending medical provider" means the same as that term is defined in Section 26-61a-102.~~

~~— [(37)] (36) "Research university" means the same as that term is defined in Section 53B-7-702 and a private, nonprofit college or university in the state that:~~

~~— (a) is accredited by the Northwest Commission on Colleges and Universities;~~

~~— (b) grants doctoral degrees; and~~

~~— (c) has a laboratory containing or a program researching a schedule I controlled substance described in Section 58-37-4.~~

~~— [(38)] (37) "State electronic verification system" means the system described in Section 26-61a-103.~~

~~— [(39)] (38) "Synthetic cannabinoid" means any cannabinoid that:~~

~~— (a) was chemically synthesized from starting materials other than a naturally occurring cannabinoid; and~~

~~— (b) is not a derivative cannabinoid.~~

~~— [(40)] (39) "Tetrahydrocannabinol" or "THC" means the same as that term is defined in Section 4-41-102.~~

~~— [(41)] (40) "THC analog" means the same as that term is defined in Section 4-41-102.~~

~~— [(42)] (41) "Total composite tetrahydrocannabinol" means all detectable forms of tetrahydrocannabinol.~~

~~— [(43)] (42) "Total tetrahydrocannabinol" or "total THC" means the same as that term is defined in Section 4-41-102.~~

‡ **26-61-201. Cannabis Research Review Board.**

## HB0230S02 compared with HB0230

(1) There is created the Cannabis Research Review Board within the department.

(2) The department shall appoint, in consultation with a professional association based in the state that represents physicians, seven members to the Cannabis Research Review Board as follows:

(a) three individuals who are medical research professionals; and

(b) four physicians ~~[who]~~:

(i) who are qualified medical providers; and

(ii) at least two who have at least 100 patients with a medical cannabis patient card at the time of appointment.

(3) The department shall ensure that at least one of the board members appointed under Subsection (2) is a member of the Controlled Substances Advisory Committee created in Section 58-38a-201.

(4) (a) Four of the board members appointed under Subsection (2) shall serve an initial term of two years and three of the board members appointed under Subsection (2) shall serve an initial term of four years.

(b) Successor board members shall each serve a term of four years.

(c) A board member appointed to fill a vacancy on the board shall serve the remainder of the term of the board member whose departure created the vacancy.

(5) The department may remove a board member without cause.

(6) The board shall:

(a) nominate a board member to serve as chairperson of the board by a majority vote of the board members; and

(b) meet as often as necessary to accomplish the duties assigned to the board under this chapter.

(7) Each board member, including the chair, has one vote.

(8) (a) A majority of board members constitutes a quorum.

(b) A vote of a majority of the quorum at any board meeting is necessary to take action on behalf of the board.

(9) A board member may not receive compensation for the member's service on the board, but may, in accordance with rules adopted by the board in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, receive:

## HB0230S02 compared with HB0230

- (a) per diem at the rate established under Section 63A-3-106; and
- (b) travel expenses at the rate established under Section 63A-3-107.

(10) If a board member appointed under Subsection (2)(b) does not meet the qualifications of Subsection (2)(b) before July 1, 2022:

- (a) the board member's seat is vacant; and
- (b) the department shall fill the vacancy in accordance with this section.

Section 2. Section ~~{26-61a-102}~~26-61a-109 is amended to read:

~~{~~ **26-61a-102. Definitions.**

~~\_\_\_\_\_~~ As used in this chapter:

~~\_\_\_\_\_~~ (1) "Active tetrahydrocannabinol" means THC, any THC analog, and tetrahydrocannabinolic acid.

~~\_\_\_\_\_~~ [(2)] (2) "Cannabis Research Review Board" means the Cannabis Research Review Board created in Section 26-61-201.]

~~\_\_\_\_\_~~ [(3)] (2) "Cannabis" means marijuana.

~~\_\_\_\_\_~~ [(4)] (3) "Cannabis cultivation facility" means the same as that term is defined in Section 4-41a-102.

~~\_\_\_\_\_~~ [(5)] (4) "Cannabis processing facility" means the same as that term is defined in Section 4-41a-102.

~~\_\_\_\_\_~~ [(6)] (5) "Cannabis product" means a product that:

~~\_\_\_\_\_~~ (a) is intended for human use; and

~~\_\_\_\_\_~~ (b) contains cannabis or any tetrahydrocannabinol or THC analog in a total concentration of 0.3% or greater on a dry weight basis.

~~\_\_\_\_\_~~ [(7)] (6) "Cannabis production establishment" means the same as that term is defined in Section 4-41a-102.

~~\_\_\_\_\_~~ [(8)] (7) "Cannabis production establishment agent" means the same as that term is defined in Section 4-41a-102.

~~\_\_\_\_\_~~ [(9)] (8) "Cannabis production establishment agent registration card" means the same as that term is defined in Section 4-41a-102.

~~\_\_\_\_\_~~ [(10)] (9) "Community location" means a public or private elementary or secondary school, a church, a public library, a public playground, or a public park.

~~\_\_\_\_\_~~ [(11)] (10) "Conditional medical cannabis card" means an electronic medical cannabis



## HB0230S02 compared with HB0230

~~card that the department issues in accordance with Subsection 26-61a-201(1)(b) to allow an applicant for a medical cannabis card to access medical cannabis during the department's review of the application.~~

~~—— [(12)] (11) "Controlled substance database" means the controlled substance database created in Section 58-37f-201.~~

~~—— [(13)] (12) "Department" means the Department of Health and Human Services.~~

~~—— [(14)] (13) "Designated caregiver" means:~~

~~—— (a) an individual:~~

~~—— (i) whom an individual with a medical cannabis patient card or a medical cannabis guardian card designates as the patient's caregiver; and~~

~~—— (ii) who registers with the department under Section 26-61a-202; or~~

~~—— (b) (i) a facility that an individual designates as a designated caregiver in accordance with Subsection 26-61a-202(1)(b); or~~

~~—— (ii) an assigned employee of the facility described in Subsection 26-61a-202(1)(b)(ii).~~

~~—— [(15)] (14) "Directions of use" means recommended routes of administration for a medical cannabis treatment and suggested usage guidelines.~~

~~—— [(16)] (15) "Dosing guidelines" means a quantity range and frequency of administration for a recommended treatment of medical cannabis.~~

~~—— [(17)] (16) "Financial institution" means a bank, trust company, savings institution, or credit union, chartered and supervised under state or federal law.~~

~~—— [(18)] (17) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy that the department authorizes, as part of the pharmacy's license, to deliver medical cannabis shipments to a medical cannabis cardholder's home address to fulfill electronic orders that the state central patient portal facilitates.~~

~~—— [(19)] (18) "Institutional review board" means an institutional review board that is registered for human subject research by the United States Department of Health and Human Services.~~

~~—— (19) "Inventory control system" means the system described in Section 4-41a-103.~~

~~—— (20) "Legal dosage limit" means an amount that:~~

~~—— (a) is sufficient to provide 30 days of treatment based on the dosing guidelines that the relevant recommending medical provider or the state central patient portal or pharmacy~~

## HB0230S02 compared with HB0230

~~medical provider, in accordance with Subsection 26-61a-502(4) or (5), recommends; and~~

~~—— (b) may not exceed:~~

~~—— (i) for unprocessed cannabis in a medicinal dosage form, 113 grams by weight; and~~

~~—— (ii) for a cannabis product in a medicinal dosage form, a quantity that contains, in total, greater than 20 grams of active tetrahydrocannabinol.~~

~~—— (21) "Legal use termination date" means a date on the label of a container of unprocessed cannabis flower:~~

~~—— (a) that is 60 days after the date of purchase of the cannabis; and~~

~~—— (b) after which, the cannabis is no longer in a medicinal dosage form outside of the primary residence of the relevant medical cannabis patient cardholder.~~

~~—— (22) "Limited medical provider" means an individual who:~~

~~—— (a) meets the recommending qualifications; and~~

~~—— (b) has no more than 15 patients with a valid medical cannabis patient card or provisional patient card as a result of the individual's recommendation, in accordance with Subsection 26-61a-106(1)(b).~~

~~—— (23) "Marijuana" means the same as that term is defined in Section 58-37-2.~~

~~—— (24) "Medical cannabis" means cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form.~~

~~—— (25) "Medical cannabis card" means a medical cannabis patient card, a medical cannabis guardian card, a medical cannabis caregiver card, or a conditional medical cannabis card.~~

~~—— (26) "Medical cannabis cardholder" means:~~

~~—— (a) a holder of a medical cannabis card; or~~

~~—— (b) a facility or assigned employee, described in Subsection(14)(b), only:~~

~~—— (i) within the scope of the facility's or assigned employee's performance of the role of a medical cannabis patient cardholder's caregiver designation under Subsection 26-61a-202(1)(b); and~~

~~—— (ii) while in possession of documentation that establishes:~~

~~—— (A) a caregiver designation described in Subsection 26-61a-202(1)(b);~~

~~—— (B) the identity of the individual presenting the documentation; and~~

~~—— (C) the relation of the individual presenting the documentation to the caregiver~~

## HB0230S02 compared with HB0230

designation:

~~—— (27) "Medical cannabis caregiver card" means an electronic document that a cardholder may print or store on an electronic device or a physical card or document that:~~

~~—— (a) the department issues to an individual whom a medical cannabis patient cardholder or a medical cannabis guardian cardholder designates as a designated caregiver; and~~

~~—— (b) is connected to the electronic verification system.~~

~~—— (28) "Medical cannabis courier" means a courier that:~~

~~—— (a) the department licenses in accordance with Section 26-61a-604; and~~

~~—— (b) contracts with a home delivery medical cannabis pharmacy to deliver medical cannabis shipments to fulfill electronic orders that the state central patient portal facilitates.~~

~~—— (29) "Medical cannabis courier agent" means an individual who:~~

~~—— (a) is an employee of a medical cannabis courier; and~~

~~—— (b) who holds a valid medical cannabis courier agent registration card.~~

~~—— (30) (a) "Medical cannabis device" means a device that an individual uses to ingest or inhale cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form:~~

~~—— (b) "Medical cannabis device" does not include a device that:~~

~~—— (i) facilitates cannabis combustion; or~~

~~—— (ii) an individual uses to ingest substances other than cannabis.~~

~~—— (31) "Medical cannabis guardian card" means an electronic document that a cardholder may print or store on an electronic device or a physical card or document that:~~

~~—— (a) the department issues to the parent or legal guardian of a minor with a qualifying condition; and~~

~~—— (b) is connected to the electronic verification system.~~

~~—— (32) "Medical cannabis patient card" means an electronic document that a cardholder may print or store on an electronic device or a physical card or document that:~~

~~—— (a) the department issues to an individual with a qualifying condition; and~~

~~—— (b) is connected to the electronic verification system.~~

~~—— (33) "Medical cannabis pharmacy" means a person that:~~

~~—— (a) (i) acquires or intends to acquire medical cannabis or a cannabis product in a medicinal dosage form from a cannabis processing facility or another medical cannabis pharmacy or a medical cannabis device; or~~

## HB0230S02 compared with HB0230

- ~~—— (ii) possesses medical cannabis or a medical cannabis device; and~~
- ~~—— (b) sells or intends to sell medical cannabis or a medical cannabis device to a medical cannabis cardholder.~~
- ~~—— (34) "Medical cannabis pharmacy agent" means an individual who:~~
  - ~~—— (a) is an employee of a medical cannabis pharmacy; and~~
  - ~~—— (b) who holds a valid medical cannabis pharmacy agent registration card.~~
- ~~—— (35) "Medical cannabis pharmacy agent registration card" means a registration card issued by the department that authorizes an individual to act as a medical cannabis pharmacy agent.~~
- ~~—— (36) "Medical cannabis shipment" means a shipment of medical cannabis or a medical cannabis product that a home delivery medical cannabis pharmacy or a medical cannabis courier delivers to a medical cannabis cardholder's home address to fulfill an electronic medical cannabis order that the state central patient portal facilitates.~~
- ~~—— (37) "Medical cannabis treatment" means cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device.~~
- ~~—— (38) (a) "Medicinal dosage form" means:~~
  - ~~—— (i) for processed medical cannabis or a medical cannabis product, the following with a specific and consistent cannabinoid content:~~
    - ~~—— (A) a tablet;~~
    - ~~—— (B) a capsule;~~
    - ~~—— (C) a concentrated liquid or viscous oil;~~
    - ~~—— (D) a liquid suspension that, after December 1, 2022, does not exceed 30 ml;~~
    - ~~—— (E) a topical preparation;~~
    - ~~—— (F) a transdermal preparation;~~
    - ~~—— (G) a sublingual preparation;~~
    - ~~—— (H) a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or rectangular cuboid shape;~~
    - ~~—— (I) a resin or wax; or~~
    - ~~—— (J) an aerosol; or~~
  - ~~—— (ii) for unprocessed cannabis flower, a container described in Section 4-41a-602 that:~~
    - ~~—— (A) contains cannabis flowers in a quantity that varies by no more than 10% from the~~

## HB0230S02 compared with HB0230

~~stated weight at the time of packaging;~~

~~—— (B) at any time the medical cannabis cardholder transports or possesses the container in public, is contained within an opaque bag or box that the medical cannabis pharmacy provides; and~~

~~—— (C) is labeled with the container's content and weight, the date of purchase, the legal use termination date, and after December 31, 2020, a barcode that provides information connected to an inventory control system; and~~

~~—— (iii) a form measured in grams, milligrams, or milliliters.~~

~~—— (b) "Medicinal dosage form" includes a portion of unprocessed cannabis flower that:~~

~~—— (i) the medical cannabis cardholder has recently removed from the container described in Subsection (38)(a)(ii) for use; and~~

~~—— (ii) does not exceed the quantity described in Subsection (38)(a)(ii).~~

~~—— (c) "Medicinal dosage form" does not include:~~

~~—— (i) any unprocessed cannabis flower outside of the container described in Subsection (38)(a)(ii), except as provided in Subsection (38)(b);~~

~~—— (ii) any unprocessed cannabis flower in a container described in Subsection (38)(a)(ii) after the legal use termination date;~~

~~—— (iii) a process of vaporizing and inhaling concentrated cannabis by placing the cannabis on a nail or other metal object that is heated by a flame, including a blowtorch; or~~

~~—— (iv) a liquid suspension that is branded as a beverage.~~

~~—— (39) "Nonresident patient" means an individual who:~~

~~—— (a) is not a resident of Utah or has been a resident of Utah for less than 45 days;~~

~~—— (b) has a currently valid medical cannabis card or the equivalent of a medical cannabis card under the laws of another state, district, territory, commonwealth, or insular possession of the United States; and~~

~~—— (c) has been diagnosed with a qualifying condition as described in Section 26-61a-104.~~

~~—— (40) "Payment provider" means an entity that contracts with a cannabis production establishment or medical cannabis pharmacy to facilitate transfers of funds between the establishment or pharmacy and other businesses or individuals.~~

~~—— (41) "Pharmacy medical provider" means the medical provider required to be on site at a medical cannabis pharmacy under Section 26-61a-403.~~

## HB0230S02 compared with HB0230

- ~~———— (42) "Provisional patient card" means a card that:~~
  - ~~———— (a) the department issues to a minor with a qualifying condition for whom:~~
    - ~~———— (i) a recommending medical provider has recommended a medical cannabis treatment;~~
    - ~~and~~
    - ~~———— (ii) the department issues a medical cannabis guardian card to the minor's parent or legal guardian; and~~
  - ~~———— (b) is connected to the electronic verification system.~~
- ~~———— (43) "Qualified medical provider" means an individual:~~
  - ~~———— (a) who meets the recommending qualifications; and~~
  - ~~———— (b) whom the department registers to recommend treatment with cannabis in a medicinal dosage form under Section 26-61a-106.~~
- ~~———— (44) "Qualified Patient Enterprise Fund" means the enterprise fund created in Section 26-61a-109.~~
- ~~———— (45) "Qualifying condition" means a condition described in Section 26-61a-104.~~
- ~~———— (46) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which:~~
  - ~~———— (a) certifies the patient's eligibility for a medical cannabis card; and~~
  - ~~———— (b) may include, at the recommending medical provider's discretion, directions of use; with or without dosing guidelines.~~
- ~~———— (47) "Recommending medical provider" means a qualified medical provider or a limited medical provider.~~
- ~~———— (48) "Recommending qualifications" means that an individual:~~
  - ~~———— (a) (i) has the authority to write a prescription;~~
  - ~~———— (ii) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah Controlled Substances Act; and~~
  - ~~———— (iii) possesses the authority, in accordance with the individual's scope of practice, to prescribe a Schedule II controlled substance; and~~
  - ~~———— (b) is licensed as:~~
    - ~~———— (i) a podiatrist under Title 58, Chapter 5a, Podiatric Physician Licensing Act;~~
    - ~~———— (ii) an advanced practice registered nurse under Title 58, Chapter 31b, Nurse Practice Act;~~

## HB0230S02 compared with HB0230

~~—— (iii) a physician under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act, or~~

~~—— (iv) a physician assistant under Title 58, Chapter 70a, Utah Physician Assistant Act.~~

~~—— (49) "State central patient portal" means the website the department creates, in accordance with Section 26-61a-601, to facilitate patient safety, education, and an electronic medical cannabis order.~~

~~—— (50) "State central patient portal medical provider" means a physician or pharmacist that the department employs in relation to the state central patient portal to consult with medical cannabis cardholders in accordance with Section 26-61a-602.~~

~~—— (51) "State electronic verification system" means the system described in Section 26-61a-103.~~

~~—— (52) "Tetrahydrocannabinol" or "THC" means a substance derived from cannabis or a synthetic equivalent as described in Subsection 58-37-4(2)(a)(iii)(AA).~~

~~—— (53) "THC analog" means the same as that term is defined in Section 4-41-102.~~

~~—— (54) "Valid form of photo identification" means any of the following forms of identification that is either current or has expired within the previous six months:~~

~~—— (a) a valid state-issued driver license or identification card;~~

~~—— (b) a valid United States federal-issued photo identification, including:~~

~~—— (i) a United States passport;~~

~~—— (ii) a United States passport card;~~

~~—— (iii) a United States military identification card; or~~

~~—— (iv) a permanent resident card or alien registration receipt card; or~~

~~—— (c) a passport that another country issued.~~

~~—— Section 3. Section ~~26-61a-105~~ is amended to read:~~

~~—— **26-61a-105. Compassionate Use Board.**~~

~~—— (1) (a) The department shall establish a Compassionate Use Board consisting of:~~

~~—— (i) seven qualified medical providers that the executive director appoints and the Senate confirms:~~

~~—— (A) who are knowledgeable about the medicinal use of cannabis;~~

~~—— (B) who are physicians licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; and~~

## HB0230S02 compared with HB0230

~~—— (C) whom the appropriate board certifies in the specialty of neurology, pain medicine and pain management, medical oncology, psychiatry, infectious disease, internal medicine, pediatrics, or gastroenterology; and~~

~~—— (ii) as a nonvoting member and the chair of the Compassionate Use Board, the executive director or the director's designee.~~

~~—— (b) In appointing the seven qualified medical providers described in Subsection (1)(a), the executive director shall ensure that at least two have a board certification in pediatrics.~~

~~—— (2) (a) Of the members of the Compassionate Use Board that the executive director first appoints:~~

~~—— (i) three shall serve an initial term of two years; and~~

~~—— (ii) the remaining members shall serve an initial term of four years.~~

~~—— (b) After an initial term described in Subsection (2)(a) expires:~~

~~—— (i) each term is four years; and~~

~~—— (ii) each board member is eligible for reappointment.~~

~~—— (c) A member of the Compassionate Use Board may serve until a successor is appointed.~~

~~—— (3) Four members constitute a quorum of the Compassionate Use Board.~~

~~—— (4) A member of the Compassionate Use Board may receive:~~

~~—— (a) notwithstanding Section 63A-3-106, compensation or benefits for the member's service; and~~

~~—— (b) travel expenses in accordance with Section 63A-3-107 and rules made by the Division of Finance in accordance with Section 63A-3-107.~~

~~—— (5) The Compassionate Use Board shall:~~

~~—— (a) review and recommend for department approval a petition to the board regarding an individual described in Subsection 26-61a-201(2)(a), a minor described in Subsection 26-61a-201(2)(c), or an individual who is not otherwise qualified to receive a medical cannabis card to obtain a medical cannabis card for compassionate use, for the standard or a reduced period of validity, if:~~

~~—— (i) for an individual who is not otherwise qualified to receive a medical cannabis card, the individual's qualified medical provider is actively treating the individual for an intractable condition that:~~



## HB0230S02 compared with HB0230

- ~~—— (A) substantially impairs the individual's quality of life; and~~
- ~~—— (B) has not, in the qualified medical provider's professional opinion, adequately responded to conventional treatments;~~
- ~~—— (ii) the qualified medical provider:~~
  - ~~—— (A) recommends that the individual or minor be allowed to use medical cannabis; and~~
  - ~~—— (B) provides a letter, relevant treatment history, and notes or copies of progress notes describing relevant treatment history including rationale for considering the use of medical cannabis; and~~
- ~~—— (iii) the Compassionate Use Board determines that:~~
  - ~~—— (A) the recommendation of the individual's qualified medical provider is justified; and~~
  - ~~—— (B) based on available information, it may be in the best interests of the individual to allow the use of medical cannabis;~~
- ~~—— (b) review and approve or deny the use of a medical cannabis device for an individual described in Subsection 26-61a-201(2)(a)(i)(B) or a minor described in Subsection 26-61a-201(2)(c) if the individual's or minor's qualified medical provider recommends that the individual or minor be allowed to use a medical cannabis device to vaporize the medical cannabis treatment;~~
- ~~—— (c) unless no petitions are pending:~~
  - ~~—— (i) meet to receive or review compassionate use petitions at least quarterly; and~~
  - ~~—— (ii) if there are more petitions than the board can receive or review during the board's regular schedule, as often as necessary;~~
- ~~—— (d) except as provided in Subsection (6), complete a review of each petition and recommend to the department approval or denial of the applicant for qualification for a medical cannabis card within 90 days after the day on which the board received the petition;~~
- ~~—— (e) consult with the department regarding the criteria described in Subsection (6); and~~
- ~~—— (f) report, before November 1 of each year, to the Health and Human Services Interim Committee:~~
  - ~~—— (i) the number of compassionate use recommendations the board issued during the past year; and~~
  - ~~—— (ii) the types of conditions for which the board recommended compassionate use.~~
- ~~—— (6) The department shall make rules, in consultation with the Compassionate Use~~

## HB0230S02 compared with HB0230

~~Board and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to establish a process and criteria for a petition to the board to automatically qualify for expedited final review and approval or denial by the department in cases where, in the determination of the department and the board:~~

~~—— (a) time is of the essence;~~

~~—— (b) engaging the full review process would be unreasonable in light of the petitioner's physical condition; and~~

~~—— (c) sufficient factors are present regarding the petitioner's safety.~~

~~—— (7) (a) (i) The department shall review:~~

~~—— (A) any compassionate use for which the Compassionate Use Board recommends approval under Subsection (5)(d) to determine whether the board properly exercised the board's discretion under this section; and~~

~~—— (B) any expedited petitions the department receives under the process described in Subsection (6):~~

~~—— (ii) If the department determines that the Compassionate Use Board properly exercised the board's discretion in recommending approval under Subsection (5)(d) or that the expedited petition merits approval based on the criteria established in accordance with Subsection (6), the department shall:~~

~~—— (A) issue the relevant medical cannabis card; and~~

~~—— (B) provide for the renewal of the medical cannabis card in accordance with the recommendation of the qualified medical provider described in Subsection (5)(a):~~

~~—— (b) (i) If the Compassionate Use Board recommends denial under Subsection (5)(d), the individual seeking to obtain a medical cannabis card may petition the department to review the board's decision:~~

~~—— (ii) If the department determines that the Compassionate Use Board's recommendation for denial under Subsection (5)(d) was arbitrary or capricious:~~

~~—— (A) the department shall notify the Compassionate Use Board of the department's determination; and~~

~~—— (B) the board shall reconsider the Compassionate Use Board's refusal to recommend approval under this section:~~

~~—— (c) In reviewing the Compassionate Use Board's recommendation for approval or~~

## HB0230S02 compared with HB0230

~~denial under Subsection (5)(d) in accordance with this Subsection (7), the department shall presume the board properly exercised the board's discretion unless the department determines that the board's recommendation was arbitrary or capricious.~~

~~— (8) Any individually identifiable health information contained in a petition that the Compassionate Use Board or department receives under this section is a protected record in accordance with Title 63G, Chapter 2, Government Records Access and Management Act.~~

~~— [(9) The Compassionate Use Board shall annually report the board's activity to the Cannabis Research Review Board.]~~

### ~~‡~~ **26-61a-109. {‡} Qualified Patient Enterprise Fund -- Creation -- Revenue neutrality.**

(1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund."

(2) The fund created in this section is funded from:

- (a) money the department deposits into the fund under this chapter;
- (b) appropriations the Legislature makes to the fund; and
- (c) the interest described in Subsection (3).

(3) Interest earned on the fund shall be deposited into the fund.

~~[(4) The department may only use money in the fund to fund the department's responsibilities under this chapter {‡}]~~

(4) Money deposited into the fund may only be used by:

(a) the department to accomplish the department's responsibilities described in this chapter; and

(b) the Center for Medical Cannabis Research created in Section 53B-17-1402 to accomplish the Center for Medical Cannabis Research's responsibilities.

(5) The department shall set fees authorized under this chapter in amounts that the department anticipates are necessary, in total, to cover the department's cost to implement this chapter.

Section ~~{4}~~3. Section ~~{26-61a-201}~~26-61a-117 is ~~{amended}~~enacted to read:

~~{26-61a-201}~~26-61a-117.~~{ Medical cannabis patient card -- Medical cannabis guardian card -- Conditional}~~ Guidance for treatment with medical cannabis~~{ card -- Application -- Fees -- Studies}~~.

## HB0230S02 compared with HB0230

~~{(1) (a) }The department{ shall, within 15 days after the day on which an individual who satisfies the eligibility criteria in this section or Section 26-61a-202 submits an application in accordance with this section or Section 26-61a-202:~~

~~—— (i) issue a medical cannabis patient card to an individual described in Subsection (2)(a);~~

~~—— (ii) issue a medical cannabis guardian card to an individual described in Subsection (2)(b);~~

~~—— (iii) issue a provisional patient card to a minor described in Subsection (2)(c); and~~

~~—— (iv) issue a medical cannabis caregiver card to an individual described in Subsection 26-61a-202(4);~~

~~—— (b) (i) Beginning on the earlier of September 1, 2021, or the date on which the electronic verification system is functionally capable of facilitating a conditional medical cannabis card under this Subsection (1)(b), upon the entry of a recommending medical provider's medical cannabis recommendation for a patient in the state electronic verification system, either by the provider or the provider's employee or by a medical cannabis pharmacy medical provider or medical cannabis pharmacy in accordance with Subsection 26-61a-501(10)(a), the department shall issue to the patient an electronic conditional medical cannabis card, in accordance with this Subsection (1)(b):~~

~~—— (ii) A conditional medical cannabis card is valid for the lesser of:~~

~~—— (A) 60 days; or~~

~~—— (B) the day on which the department completes the department's review and issues a medical cannabis card under Subsection (1)(a), denies the patient's medical cannabis card application, or revokes the conditional medical cannabis card under Subsection (8);~~

~~—— (iii) The department may issue a conditional medical cannabis card to an individual applying for a medical cannabis patient card for which approval of the Compassionate Use Board is not required;~~

~~—— (iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and obligations under law applicable to a holder of the medical cannabis card for which the individual applies and for which the department issues the conditional medical cannabis card.~~

~~—— (2) (a) An individual is eligible for a medical cannabis patient card if:~~

~~—— (i) (A) the individual is at least 21 years old; or~~

## HB0230S02 compared with HB0230

~~\_\_\_\_\_ (B) the individual is 18, 19, or 20 years old, the individual petitions the Compassionate Use Board under Section 26-61a-105, and the Compassionate Use Board recommends department approval of the petition;~~

~~\_\_\_\_\_ (ii) the individual is a Utah resident;~~

~~\_\_\_\_\_ (iii) the individual's recommending medical provider recommends}, in consultation with the Center for Medical Cannabis Research created in Section 53B-17-1402, shall:~~

~~\_\_\_\_\_ (1) develop evidence-based guidance for treatment with medical cannabis ~~fin~~ accordance with Subsection (4);~~

~~\_\_\_\_\_ (iv) the individual signs an acknowledgment stating that the individual received the information} based on the latest medical research that shall include:~~

~~\_\_\_\_\_ (a) for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis;~~

~~\_\_\_\_\_ (b) risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and~~

~~\_\_\_\_\_ (c) potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration; and~~

~~\_\_\_\_\_ (2) educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding:~~

~~\_\_\_\_\_ (a) the evidence-based guidance for treatment with medical cannabis described in Subsection ~~(9)~~; and~~

~~\_\_\_\_\_ (v) the individual pays to the department a fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504;~~

~~\_\_\_\_\_ (b) (i) An individual is eligible for a ~~1~~ (a);~~

~~\_\_\_\_\_ (b) relevant warnings and safety information related to medical cannabis ~~guardian~~ card if the individual;~~

~~\_\_\_\_\_ (A) is at least 18 years old;~~

~~\_\_\_\_\_ (B) is a Utah resident;~~

~~\_\_\_\_\_ (C) is the parent or legal guardian of a minor for whom the minor's qualified medical provider recommends a} use; and~~

~~\_\_\_\_\_ (c) other topics related to medical cannabis ~~treatment, the individual petitions the~~ Compassionate Use Board under Section 26-61a-105, and the Compassionate Use Board~~

## HB0230S02 compared with HB0230

recommends department approval of the petition;

—— (D) the individual signs an acknowledgment stating that the individual received the information described in Subsection (9);

—— (E) pays to the department a fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504, plus the cost of the criminal background check described in Section 26-61a-203; and

—— (F) the individual has not been convicted of a misdemeanor or felony drug distribution offense under either state or federal law, unless the individual completed any imposed sentence six months or more before the day on which the individual applies for a medical cannabis guardian card.

—— (ii) The department shall notify the Department of Public Safety of each individual that the department registers for a medical cannabis guardian card.

—— (c) (i) A minor is eligible for a provisional patient card if:

—— (A) the minor has a qualifying condition;

—— (B) the minor's qualified medical provider recommends a medical cannabis treatment to address the minor's qualifying condition;

—— (C) one of the minor's parents or legal guardians petitions the Compassionate Use Board under Section 26-61a-105, and the Compassionate Use Board recommends department approval of the petition; and

—— (D) the minor's parent or legal guardian is eligible for a medical cannabis guardian card under Subsection (2)(b) or designates a caregiver under Subsection (2)(d) who is eligible for a medical cannabis caregiver card under Section 26-61a-202.

—— (ii) The department shall automatically issue a provisional patient card to the minor described in Subsection (2)(c)(i) at the same time the department issues a medical cannabis guardian card to the minor's parent or legal guardian.

—— (d) Beginning on the earlier of September 1, 2021, or the date on which the electronic verification system is functionally capable of servicing the designation, if the parent or legal guardian of a minor described in Subsections (2)(c)(i)(A) through (C) does not qualify for a medical cannabis guardian card under Subsection (2)(b), the parent or legal guardian may designate up to two caregivers in accordance with Subsection 26-61a-202(1)(c) to ensure that the minor has adequate and safe access to the recommended medical cannabis treatment.

## HB0230S02 compared with HB0230

~~—— (3) (a) An individual who is eligible for a medical cannabis card described in Subsection (2)(a) or (b) shall submit an application for a medical cannabis card to the department:~~

~~—— (i) through an electronic application connected to the state electronic verification system;~~

~~—— (ii) with the recommending medical provider; and~~

~~—— (iii) with information including:~~

~~—— (A) the applicant's name, gender, age, and address;~~

~~—— (B) the number of the applicant's valid form of photo identification;~~

~~—— (C) for a medical cannabis guardian card, the name, gender, and age of the minor receiving a medical cannabis treatment under the cardholder's medical cannabis guardian card; and~~

~~—— (D) for a provisional patient card, the name of the minor's parent or legal guardian who holds the associated medical cannabis guardian card.~~

~~—— (b) The department shall ensure that a medical cannabis card the department issues under this section contains the information described in Subsection (3)(a)(iii):~~

~~—— (c) (i) If a recommending medical provider determines that, because of age, illness, or disability, a medical cannabis patient cardholder requires assistance in administering the medical cannabis treatment that the recommending medical provider recommends, the recommending medical provider may indicate the cardholder's need in the state electronic verification system, either directly or, for a limited medical provider, through the order described in Subsections 26-61a-106(1)(c) and (d):~~

~~—— (ii) If a recommending medical provider makes the indication described in Subsection (3)(c)(i):~~

~~—— (A) the department shall add a label to the relevant medical cannabis patient card indicating the cardholder's need for assistance;~~

~~—— (B) any adult who is 18 years old or older and who is physically present with the cardholder at the time the cardholder needs to use the recommended medical cannabis treatment may handle the medical cannabis treatment and any associated medical cannabis device as needed to assist the cardholder in administering the recommended medical cannabis treatment; and~~

## HB0230S02 compared with HB0230

~~—— (C) an individual of any age who is physically present with the cardholder in the event of an emergency medical condition, as that term is defined in Section 31A-1-301, may handle the medical cannabis treatment and any associated medical cannabis device as needed to assist the cardholder in administering the recommended medical cannabis treatment.~~

~~—— (iii) A non-cardholding individual acting under Subsection (3)(c)(ii)(B) or (C) may not:~~

~~—— (A) ingest or inhale medical cannabis;~~

~~—— (B) possess, transport, or handle medical cannabis or a medical cannabis device outside of the immediate area where the cardholder is present or with an intent other than to provide assistance to the cardholder; or~~

~~—— (C) possess, transport, or handle medical cannabis or a medical cannabis device when the cardholder is not in the process of being dosed with medical cannabis;~~

~~—— (4) To recommend a medical cannabis treatment to a patient or to renew a recommendation, a recommending medical provider shall:~~

~~—— (a) before recommending or renewing a recommendation for medical cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form:~~

~~—— (i) verify the patient's and, for a minor patient, the minor patient's parent or legal guardian's valid form of identification described in Subsection (3)(a);~~

~~—— (ii) review any record related to the patient and, for a minor patient, the patient's parent or legal guardian in:~~

~~—— (A) for a qualified medical provider, the state electronic verification system; and~~

~~—— (B) the controlled substance database created in Section 58-37f-201; and~~

~~—— (iii) consider the recommendation in light of the patient's qualifying condition, history of substance use or opioid use disorder, and history of medical cannabis and controlled substance use during an initial face-to-face visit with the patient; and~~

~~—— (b) state in the recommending medical provider's recommendation that the patient:~~

~~—— (i) suffers from a qualifying condition, including the type of qualifying condition; and~~

~~—— (ii) may benefit from treatment with cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form;~~

~~—— (5) (a) Except as provided in Subsection (5)(b) or (c), a medical cannabis card that the department issues under this section is valid for the lesser of:~~

~~—— (i) an amount of time that the recommending medical provider determines; or~~



## HB0230S02 compared with HB0230

- ~~—— (ii) (A) six months for the first issuance, and, except as provided in Subsection (5)(a)(ii)(B), for a renewal; or~~
- ~~—— (B) for a renewal, one year if, after at least one year following the issuance of the original medical cannabis card, the recommending medical provider determines that the patient has been stabilized on the medical cannabis treatment and a one-year renewal period is justified.~~
- ~~—— (b) (i) A medical cannabis card that the department issues in relation to a terminal illness described in Section 26-61a-104 expires after one year.~~
- ~~—— (ii) The recommending medical provider may revoke a recommendation that the provider made in relation to a terminal illness described in Section 26-61a-104 if the medical cannabis cardholder no longer has the terminal illness.~~
- ~~—— (c) A medical cannabis card that the department issues in relation to acute pain as described in Section 26-61a-104 expires 30 days after the day on which the department first issues a conditional or full medical cannabis card.~~
- ~~—— (6) (a) A medical cannabis patient card or a medical cannabis guardian card is renewable if:~~
- ~~—— (i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a) or (b); or~~
- ~~—— (ii) the cardholder received the medical cannabis card through the recommendation of the Compassionate Use Board under Section 26-61a-105.~~
- ~~—— (b) The recommending medical provider who made the underlying recommendation for the card of a cardholder described in Subsection (6)(a) may renew the cardholder's card through phone or video conference with the cardholder, at the recommending medical provider's discretion.~~
- ~~—— (c) Before having access to a renewed card, a cardholder under Subsection (2)(a) or (b) shall pay to the department a renewal fee in an amount that:~~
- ~~—— (i) subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504; and~~
- ~~—— (ii) may not exceed the cost of the relatively lower administrative burden of renewal in comparison to the original application process.~~
- ~~—— (d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional~~

## HB0230S02 compared with HB0230

~~patient card renews automatically at the time the minor's parent or legal guardian renews the parent or legal guardian's associated medical cannabis guardian card:~~

~~—— (7) (a) A cardholder under this section shall carry the cardholder's valid medical cannabis card with the patient's name:~~

~~—— (b) (i) A medical cannabis patient cardholder or a provisional patient cardholder may purchase, in accordance with this chapter and the recommendation underlying the card, cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device:~~

~~—— (ii) A cardholder under this section may possess or transport, in accordance with this chapter and the recommendation underlying the card, cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device:~~

~~—— (iii) To address the qualifying condition underlying the medical cannabis treatment recommendation:~~

~~—— (A) a medical cannabis patient cardholder or a provisional patient cardholder may use cannabis in a medicinal dosage form, a medical cannabis product in a medicinal dosage form, or a medical cannabis device; and~~

~~—— (B) a medical cannabis guardian cardholder may assist the associated provisional patient cardholder with the use of cannabis in a medicinal dosage form, a medical cannabis product in a medicinal dosage form, or a medical cannabis device:~~

~~—— (8) The department may revoke a medical cannabis card that the department issues under this section if the cardholder:~~

~~—— (a) violates this chapter; or~~

~~—— (b) is convicted under state or federal law of, after March 17, 2021, a drug distribution offense:~~

~~—— (9) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, a process to provide information regarding the following to an individual receiving a medical cannabis card:~~

~~—— (a) risks associated with medical cannabis treatment;~~

~~—— (b) the fact that a condition's listing as a qualifying condition does not suggest that medical cannabis treatment is an effective treatment or cure for that condition, as described in Subsection 26-61a-104(1); and~~

## HB0230S02 compared with HB0230

- ~~—— (c) other relevant warnings and safety information that the department determines.~~
- ~~—— (10) The department may establish procedures by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to implement the application and issuance provisions of this section.~~
- ~~—— (11) (a) On or before September 1, 2021, the department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, a process to allow an individual from another state to register with the department in order to purchase medical cannabis or a medical cannabis device from a medical cannabis pharmacy while the individual is visiting the state.~~
- ~~—— (b) The department may only provide the registration process described in Subsection (11)(a):~~
  - ~~—— (i) to a nonresident patient; and~~
  - ~~—— (ii) for no more than two visitation periods per calendar year of up to 21 calendar days per visitation period.~~
- ~~—— (12) (a) A person may submit to the department a request to conduct a research study using medical cannabis cardholder data that the state electronic verification system contains.~~
- ~~—— (b) The department shall review a request described in Subsection (12)(a) to determine whether an institutional review board[, as that term is defined in Section 26-61-102,] could approve the research study.~~
- ~~—— (c) At the time an individual applies for a medical cannabis card, the department shall notify the individual:~~
  - ~~—— (i) of how the individual's information will be used as a cardholder;~~
  - ~~—— (ii) that by applying for a medical cannabis card, unless the individual withdraws consent under Subsection (12)(d), the individual consents to the use of the individual's information for external research; and~~
  - ~~—— (iii) that the individual may withdraw consent for the use of the individual's information for external research at any time, including at the time of application.~~
- ~~—— (d) An applicant may, through the medical cannabis card application, and a medical cannabis cardholder may, through the state central patient portal, withdraw the applicant's or cardholder's consent to participate in external research at any time.~~
- ~~—— (e) The department may release, for the purposes of a study described in this~~

## HB0230S02 compared with HB0230

~~Subsection (12), information about a cardholder under this section who consents to participate under Subsection (12)(c):~~

~~— (f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of consent:~~

~~— (i) applies to external research that is initiated after the withdrawal of consent; and~~

~~— (ii) does not apply to research that was initiated before the withdrawal of consent.~~

~~— (g) The department may establish standards for a medical research study's validity, by rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.~~

~~— (13) The department shall record the issuance or revocation of a medical cannabis card under this section in the controlled substance database.~~

~~— Section 5}use as determined by the department.~~

Section 4. Section **26-61a-703** is amended to read:

### **26-61a-703. Report.**

(1) By the November interim meeting each year beginning in 2020, the department shall report to the Health and Human Services Interim Committee on:

(a) the number of applications and renewal applications filed for medical cannabis cards;

(b) the number of qualifying patients and designated caregivers;

(c) the nature of the debilitating medical conditions of the qualifying patients;

(d) the age and county of residence of cardholders;

(e) the number of medical cannabis cards revoked;

(f) the number of practitioners providing recommendations for qualifying patients;

(g) the number of license applications and renewal license applications received;

(h) the number of licenses the department has issued in each county;

(i) the number of licenses the department has revoked;

(j) the quantity of medical cannabis shipments that the state central patient portal facilitates;

(k) the number of overall purchases of medical cannabis and medical cannabis products from each medical cannabis pharmacy;

(l) the expenses incurred and revenues generated from the medical cannabis program;

and

## HB0230S02 compared with HB0230

(m) an analysis of product availability in medical cannabis pharmacies.

(2) The report shall include information provided by the Center for Medical Cannabis Research described in Section 53B-17-1402.

~~[(2)]~~ (3) The department may not include personally identifying information in the report described in this section.

~~[(3)]~~ (4) During the 2022 legislative interim, the department shall report to the working group described in Section 36-12-8.2 as requested by the working group.

Section ~~{6}~~5. Section **53B-17-1401** is enacted to read:

### CHAPTER 17. UNIVERSITY OF UTAH

#### Part 14. Center for Medical Cannabis Research

##### **53B-17-1401. Definitions.**

As used in this part:

(1) "Academic research cannabis license" means the license described in Title 4, Chapter 41a, Part 9, Academic Medical Cannabis Research.

(2) "Cannabis" means the same as that term is defined in Section 26-61a-102.

(3) "Cannabis cultivation facility" means the same as that term is defined in Section 4-41a-102.

(4) "Cannabis product" means the same as that term is defined in Section 26-61a-102.

(5) "Center" means the Center for the Medical Cannabis Research created in Section 53B-17-1402.

(6) "Eligible institution" means an institution of higher education that:

(a) is located in Utah; and

(b) has or will obtain an academic research cannabis license.

(7) "Medical cannabis patient card" means the same as that term is defined in Section 26-61a-102.

Section ~~{7}~~6. Section **53B-17-1402** is enacted to read:

##### **53B-17-1402. Center creation -- Duties.**

(1) There is created the Center for Medical Cannabis Research within the University of Utah.

(2) The center:

(a) shall seek state, federal, and private funds to award grants for medical cannabis

## HB0230S02 compared with HB0230

research;

(b) shall facilitate and support funding for research related to the health effects, including the potential risks or side effects, of the use of cannabis products;

(c) shall facilitate and support funding for research related to the efficacy and potential health effects of various cannabis delivery methods, including vaporizing, ingesting, topical application, and combustion;

(d) shall support researchers in applying for and securing federal and private research grant funding for expanding medical cannabis research;

(e) shall review current and future cannabis research literature, clinical studies, and clinical trials;

(f) shall educate medical providers, lawmakers, and the public about medical cannabis research advances;

(g) shall, if requested, consult with researchers and eligible institutions seeking to conduct medical cannabis research regarding legal implications of the research under state and federal law;

(h) shall monitor, to the extent that appropriate and sufficient data are available, patient outcomes in any state with a medicinal cannabis program;

(i) may coordinate, share knowledge, and share best practices with a state:

(i) that has a medical cannabis program; and

(ii) is conducting cannabis research;

(j) may award or facilitate funding for grants to an eligible institution for medical cannabis research, including research regarding the growing of a medical-grade cannabis plant that is used for a cannabis product;

(k) shall support a licensed cannabis cultivation facility to provide medical-grade cannabis products for research;

(l) shall make ~~any~~, **for** research conducted by the center, **the research outcomes** publicly available;

(m) shall maintain a catalog of all published scientific reports based on projects funded or managed by the center;

(n) shall ensure that an individual who agrees to use a cannabis product as part of a research project conducted by the center or a grantee has:

## HB0230S02 compared with HB0230

(i) a valid medical cannabis patient card from the state; or  
(ii) if included in the research project as a resident of another state, the equivalent of a medical cannabis patient card under the laws of another state, district, territory, commonwealth, or insular possession of the United States;

(o) shall obtain an academic research cannabis license;

(p) may apply for, or assist an eligible institution to apply for, a federal cannabis cultivation registration to locate a cannabis cultivation site in Utah; and

(q) for the report described in Section 26-61a-703, shall provide information to the Department of Health and Human Services describing:

(i) all research projects that are funded by a grant awarded by the center, including which institution received the grant; ~~and~~

(ii) all research projects conducted by the center ~~;~~

~~(3); and~~

(iii) the adequacy of funding for the center's duties.

(3) For research funded, conducted, or facilitated by the center, the center shall ensure the research:

(a) includes appropriate research development, testing, and evaluation; and

(b) if the research involves human subjects, is reviewed, approved, and overseen by an institutional review board as defined in Section 26-61-102.

(4) The University of Utah shall provide staff for the center.

Section ~~{8}~~7. ~~{Repealer}~~.

~~This bill repeals:~~

~~Section 26-61-101, Title.~~

~~Section 26-61-102, Definitions.~~

~~Section 26-61-103, Institutional review board -- Approved study of cannabis, a cannabinoid product, or an expanded cannabinoid product.~~

~~Section 26-61-201, }Appropriation.~~

The following sums of money are appropriated for the fiscal year beginning July 1, 2023, and ending June 30, 2024. These are additions to amounts previously appropriated for fiscal year 2024. Under the terms and conditions of Title 63J, Chapter 1, Budgetary Procedures Act, the Legislature appropriates the following sums of money from the funds or accounts

**HB0230S02 compared with HB0230**

indicated for the use and support of the government of the state of Utah.

ITEM 1

To University of Utah - Education and General

From Qualified Patient Enterprise Fund 650,000

Schedule of Programs:

Center for Medical Cannabis Research 650,000

The Legislature intends that the Center for Medical Cannabis Research ~~Review Board.~~

~~Section 26-61-202, Duties.~~

~~(center) use the appropriation under this item to carry out the center's duties described in~~

~~Section 53B-17-1402.~~